Capture Pharmaceuticals, Inc.

Biotech · Private

Small molecule chelator (CE) that binds and removes gadolinium and radioactive actinides from patient tissues

Grants
$3.4M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · C2E2-An Orally Administered Radionuclide Decorporation Agent$742,768
Federal grantDepartment of Health and Human Services · Phase II · C2E2-An Orally Administered Radionuclide Decorporation Agent$1,484,404
Federal grantDepartment of Health and Human Services · Phase I · Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents$205,593
Federal grantDepartment of Health and Human Services · Phase I · Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents$205,593
Federal grantDepartment of Health and Human Services · Phase II · C2E2-An Orally Administered Radionuclide Decorporation Agent$741,636
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2702DUB THERAPEUTICS INC.——
2703EDI THERAPEUTICS LLC——
2704OSEM FLUIDICS INC——
2705Capture Pharmaceuticals, Inc.——
2706Helicore Biopharma——
2707VELAKOR BIOTHERAPEUTICS, INC.——
2708Alltrna——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.